CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 194 enrolled
Drug / intervention
Encepur Adultsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03294135
NCT03294135Phase 4Completed
CompareCT.gov

Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

GlaxoSmithKline·interventional·Posted Sep 26, 2017·Updated Mar 28, 2024

In Brief

A Phase 4 clinical trial evaluating Encepur Adults for Virus Diseases. Completed, enrolled 194 participants across 1 site.

Detailed Summary

The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine. This study will further investigate the booster response in subjects who will receive their second booster dose\* in this study. \* Any booster given in this study will be the second that the subject has received (with regard to the follow-up of the previous study).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVirus Diseases
CountriesCzechia
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 26, 2017
Enrollment StartOct 5, 2017
Primary CompletionOct 25, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.8 years ago

Interventions

Encepur Adultsbiological

One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.